Equities

CARsgen Therapeutics Holdings Ltd

CARsgen Therapeutics Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.02
  • Today's Change-0.20 / -2.77%
  • Shares traded9.53m
  • 1 Year change-38.20%
  • Beta1.0607
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

  • Revenue in HKD (TTM)6.81m
  • Net income in HKD-746.44m
  • Incorporated--
  • Employees477.00
  • Location
    CARsgen Therapeutics Holdings LtdBuilding 12No.388 Yindu Road, Xuhui DistrictSHANGHAI KY1-1205ChinaCHN
  • Websitehttps://www.carsgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Frontage Holdings Corp2.02bn47.47m2.18bn1.66k46.600.83156.441.080.0230.0230.9881.290.470156.234.581,150,374.001.064.461.305.2828.5634.002.269.921.252.370.3110.003.7925.61-58.00-0.782640.43--
Biocytogen Pharmaceuticals Beijng Co Ltd859.97m-261.91m2.40bn1.04k--3.02--2.79-0.6576-0.65762.161.990.310923.645.36806,728.50-9.47---12.44--71.97---30.46--1.33-4.180.436--34.28--36.38------
CStone Pharmaceuticals490.40m-152.87m2.56bn164.00--5.09--5.21-0.12-0.120.38470.39120.28611.332.502,132,195.00-8.92-54.76-16.99-81.6870.73---31.17-301.621.45--0.4171---3.64--59.32--52.42--
ImmuneOnco Biopharmaceuticls Shanghi Inc404.97k-402.17m2.74bn150.00--4.25--6,772.28-1.12-1.120.00111.72------2,792.90-------------99,307.43------0.14---28.25--5.82------
Abbisko Cayman Ltd534.17m-17.40m3.15bn275.00--1.41886.045.89-0.0295-0.02950.82253.270.2159--65.752,070,417.00-0.7034---0.733--0.00---3.26------0.0142------12.92------
CARsgen Therapeutics Holdings Ltd6.81m-746.44m4.13bn477.00--2.58--605.92-1.34-1.340.01222.790.0027--0.30213,198.43-29.27---32.86--25.50---10,960.25--9.44--0.1246------16.19------
Alphamab Oncology274.85m-231.63m4.41bn429.00--2.53--16.04-0.2406-0.24060.28551.810.11450.825613.94631,848.10-9.65-18.72-11.16-21.9479.33---84.27-415.554.42--0.167--31.12--35.35---13.12--
Laekna Inc0.00-317.46m5.19bn92.00--7.14-----0.8909-0.89090.001.860.00----0.00-31.46---35.71--------------0.0856------52.81------
Lepu Biopharma Co Ltd220.30m-78.01m5.22bn491.00--5.31383.5923.68-0.0462-0.04620.13230.57440.08471.861.53513,514.70-3.53---5.72--78.76---41.62--0.7322-2.710.4621--1,347.16--96.79------
Data as of Nov 22 2024. Currency figures normalised to CARsgen Therapeutics Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.76%Per cent of shares held by top holders
HolderShares% Held
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 202421.24m3.72%
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 202413.34m2.33%
The Vanguard Group, Inc.as of 06 Nov 202412.68m2.22%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20245.29m0.93%
GF Fund Management Co., Ltd.as of 30 Jun 20244.95m0.87%
E Fund Management Co., Ltd.as of 30 Jun 20242.83m0.50%
Bosera Asset Management Co., Ltd.as of 30 Jun 20242.71m0.47%
China Asset Management Co., Ltd.as of 30 Jun 20241.99m0.35%
Tian Hong Asset Management Co., Ltd.as of 30 Jun 20241.39m0.24%
Fullgoal Asset Management (HK) Ltd.as of 30 Jun 2024798.00k0.14%
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.